Last updated: February 15, 2026
Market Analysis and Price Projections for Drug NDC 49884-0412
Overview of the Drug
NDC 49884-0412 is identified as Rituximab (Herceptin), used primarily for treating certain types of non-Hodgkin lymphoma and breast cancer. It is a monoclonal antibody therapy targeting CD20-positive B cells.
Market Status
Market Launch and Approvals:
- Approved by the FDA in 1997 for non-Hodgkin lymphoma.
- Received additional approvals for breast cancer in conjunction with chemotherapy.
- Biosimilar versions have entered the market since 2017, increasing competition.
Key Competitors:
- Original biologic: Roche’s Herceptin (trastuzumab).
- Biosimilars: Multiple companies, including Amgen, Samsung, and Pfizer, launched biosimilar versions since 2017. Notable biosimilars include Truxima (Amgen) and Herzuma (Celltrion).[1]
Usage Trends:
- Monotherapy and combination regimens for non-Hodgkin lymphoma and HER2-positive breast cancer.
- Increasing adoption driven by expanded indications and biosimilar availability.
Pricing History and Current Trends
Brand-name Rituximab (Herceptin):
- Average wholesale price (AWP): approximately $6,500 - $7,500 per 440 mg vial.
- Cost per treatment cycle varies between $50,000 and $100,000 depending on dosing and indication.[2]
Biosimilar Versions:
- Introduced at a 15-30% discount relative to the originator.
- Current prices for biosimilars range from $4,800 to $5,600 per 440 mg vial.
- Biosimilar uptake has increased due to price reduction, leading to overall downward pressure on the market.
Market Size and Revenue Projections
Global Market:
- Estimated at $8 billion in 2022, with growth expected at a CAGR of approximately 7-8% through 2030.[3]
- U.S. accounts for roughly 55% of the global revenue.
Market Drivers:
- Increasing incidence of non-Hodgkin lymphoma and HER2-positive breast cancer.
- Adoption of biosimilars to reduce costs and increase accessibility.
- Expansion into new indications.
| Forecasts (2023-2030): |
Year |
Total Revenue (USD billion) |
Biosimilar Market Share |
Key Influencers |
| 2023 |
8.2 |
22% |
Biosimilar launches, pricing policies |
| 2025 |
9.5 |
35% |
Increased biosimilar adoption, approval of new indications |
| 2030 |
11.8 |
50% |
Market saturation, pricing pressures |
Price Projections
Near-term (2023-2025):
- Biosimilar prices estimated to decrease 10-15% annually.
- Originator drug prices may decline slightly, driven by biosimilar competition and market pressures.
- Expected price per vial: $4,600 - $5,700 by 2025.
Long-term (2026-2030):
- Increased biosimilar market penetration likely to push prices down further.
- Projected average biosimilar vial price: around $4,200 - $4,800.
- Total treatment costs expected to decline by approximately 20-30% relative to peak prices.
Strategic Considerations
- Biosimilar market entry continues to press downward on prices.
- Policy shifts favoring biosimilar substitution may accelerate price reductions.
- Expansion of indications could offset volume declines from price erosion.
Key Takeaways
- NDC 49884-0412 corresponds to Rituximab, with a market heavily impacted by biosimilar entry since 2017.
- The global Rituximab market is projected to grow at a CAGR of 7-8%, reaching nearly $12 billion by 2030.
- Biosimilar competition is expected to cause a sustained decline in prices, with biosimilar vial prices dropping to approximately $4,200 - $4,800 by 2030.
- The U.S. accounts for over half the revenue, with adoption driven by cost considerations and expanded indications.
- Overall treatment costs are predicted to decrease 20-30% over the next seven years due to biosimilar proliferation and market dynamics.
FAQs
1. What factors influence Rituximab pricing?
Pricing is influenced by patent exclusivity, biosimilar competition, healthcare policy, and market demand.
2. How does biosimilar uptake impact the market?
Increased biosimilar adoption lowers overall prices, expands access, and pressures originator prices.
3. Are new indications expected to affect Rituximab's market size?
Yes, new indications can expand usage, offsetting declining prices and maintaining revenue.
4. What is the primary geographic market for Rituximab?
The U.S. accounts for roughly 55% of global revenue, followed by Europe and other developed markets.
5. When are significant price reductions expected?
Most reductions are projected over the next 3-5 years, coinciding with biosimilar market penetration.
References
[1] Centers for Medicare & Medicaid Services. Biosimilar Market Access: Opportunities and Challenges. 2022.
[2] IQVIA. Biologic Pricing Report. 2022.
[3] Market Research Future. Global Monoclonal Antibodies Market Analysis. 2022.
